The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, became efficient for treating the enthesitis and dactylitis parts of psoriatic arthritis…
The monoclonal antibody guselkumab (Tremfya), which targets the p19 subunit of interleukin (IL)-23, became efficient for treating the enthesitis and dactylitis parts of psoriatic arthritis…